

- Abbot Laboratories**
Research centre closing, Quebec, 10:12
- Access to Information Act**
Legislation, Bill C-22 cost impact studies, Young requesting, 11:61-2; 16:14
- Acquired Immune Deficiency Syndrome** *see* AIDS
- Adam, Guy** (Canadian Health Coalition)
Patent Act (amdt.)(Bill C-22), 7:3-4, 13, 18
- Aerospace industry**
Research and development, 14:25
- Agenda and procedure subcommittee** *see* Procedure and Committee business
- Agricultural chemicals**
Compulsory licensing, possibility, 11:74-5
- AIDS** *see* Diseases
- Alberta** *see* Drug plans; Universities
- Alexander, Taylor** (Canadian Association of Social Workers)
Patent Act (amdt.)(Bill C-22), 11:52-6, 59, 64, 66
- Altamira**
Venture capital company, 8:53
- Alzheimer's disease** *see* Brand name drugs—Availability in Canada
- American Association of Retired Persons**
Legislation, Bill C-22 views, 12:21, 23-4; 15:56, 64
- Andre, Hon. Harvie** (PC—Calgary Centre; Minister of Consumer and Corporate Affairs)
Access to Information Act, legislation, 16:14
Biotech, 1:45
Biotechnology industry, 17:49
New Democratic Party position, 1:24
Stimulating, 1:24, 30
Brand name drugs
Exclusivity period from imports, 1:12-3, 18-21, 24-5, 33, 45; 16:18, 83-7; 17:22-5
Intellectual property protection, 16:64
Market share, 1:12
Multinational corporations' dominance, 1:19-20
Research and development record, 16:86-7
Cangene Corp., 16:61
Consumer and Corporate Affairs Department, Canadian Patent Office, 16:43
Drug patents, 17:51
Applications, 16:37, 42, 44
First-to-file system, 16:47-8, 50-1
Processing timeframe, 1:11
Product vs process patent, 1:13-4; 16:18, 58-63; 17:48-9
Drug Prices Review Board
Appointments process, 16:24; 17:34-5
Constitutionality, 16:68-9
Legislation, 1:12, 15, 33
Prices, 16:23, 70-1; 17:36-8
Regulatory powers, 1:14, 38-9; 16:72-5; 17:26
Reporting responsibilities, 17:38-9, 41
Drugs and pharmaceuticals
Costs/prices, 1:13, 15-8, 25, 28-33, 36, 40, 43-5; 16:86
Provinces, 1:14-5, 18-9, 25-7
Drugs and pharmaceuticals industry
Growth, 1:15
Profits, 1:23-4
- Andre, Hon. Harvie—Cont.**
Drugs and pharmaceuticals industry—*Cont.*
Research and development, 1:16-8, 22, 33-4, 45
Sales, 1:13
Self-insurance, 1:27
Transfer pricing issue, 1:38-9
Generic drugs
Compulsory licensing, 1:11-2, 15, 31-2; 16:79-80, 82
Manufactured in Canada, 1:12-3, 15
Market entry timeframe, 1:11-2
Market share, 1:12
IMS, 16:74
Ontario, 17:19-21
Ouellet, references, 16:12
Patent Act (amdt.)(Bill C-22), 1:11-41, 43-5; 16:11-9, 23-5, 27-8, 33, 37-8, 41-8, 50-1, 58-65, 68-76, 78-80, 82-7; 17:19-29, 34-9, 41-3, 48-51
Provinces, legislation, 1:38, 43
Quebec Federation of Senior Citizens., 1:36
References *see* Canadian Drug Manufacturers Association; Canadian Health Coalition; Consumer and Corporate Affairs Department; Drug plans; Drugs and pharmaceuticals—Costs/prices; McMaster University Faculty of Health Sciences—Students; Montreal Board of Trade; National Federation of Nurses' Unions—Background; Patent Act (amdt.)(Bill C-22)—References; Pharmaceutical Manufacturers Association of Canada; Quebec Federation of Senior Citizens; Saskatchewan—Government
Scientific Research Tax Credit Program, legislation, 17:23-4
Senior citizens, legislation, 1:36
Smith, Kline and French Canada Ltd., Attorney General of Canada lawsuit, 16:69
Stetler, references, 1:38
Universities, research and development, 16:84-5
- Angus Reid & Associates** *see* Drugs and pharmaceuticals—Costs/prices
- Animals** *see* Genetic animals
- Antoft, Prof. Kell** (Individual presentation)
Patent Act (amdt.)(Bill C-22), 11:3, 5-17
References, background, 11:8-9
- Apotex**
Patent record, 3:38
Sales, research and development, employment, etc., 3:36-7, 50-1
- Appendices**
McMaster University Faculty of Health Sciences, Dean's letter, 10A:1-2
See also Procedure and Committee business—Documents
- Atlantic provinces** *see* Drugs and pharmaceuticals industry—Research and development, Employment
- Attorney General of Canada** *see* Smith, Kline and French Canada Ltd.
- August, Casey** (Patent and Trademark Institute)
Patent Act (amdt.)(Bill C-22), 6:5, 10-1, 17
- Austen, Walter** (Green Shield Prepaid Services)
Patent Act (amdt.)(Bill C-22), 6:4, 77-8, 80-2, 84-7
- Automotive industry**
Research and development/branch plant status, 14:24-5
- Ayerst Laboratories**, 3:38; 6:45; 10:12-3
Canadian origin, Montreal, Que., United States take-over, 6:51; 11:10, 14